You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 11,311,541


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,311,541 protect, and when does it expire?

Patent 11,311,541 protects REZUROCK and is included in one NDA.

This patent has one patent family member in one country.

Summary for Patent: 11,311,541
Title:Treatment of GVHD
Abstract: The invention relates to treatment of graft versus host disease (GVHD) using compounds that inhibit ROCK2. In preferred aspects, the present invention provides methods for the treatment of GVHD, including chronic GVHD (cGVHD) using compounds having the formulae 1-XXV, as set forth herein.
Inventor(s): Zanin-Zhorov; Alexandra (Staten Island, NY), Blazar; Bruce Robert (Golden Valley, MN), Flynn; Ryan (Minneapolis, MN)
Assignee: KADMON CORPORATION, LLC (New York, NY) REGENTS OF THE UNIVERSITY OF MINNESOTA (Minneapolis, MN)
Application Number:15/303,420
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of US Patents: A Detailed Analysis

Introduction

The landscape of patent law in the United States is complex and evolving, particularly with the recent updates and guidance from the US Patent and Trademark Office (USPTO). For innovators and patent practitioners, understanding the scope and claims of patents is crucial for navigating the patent eligibility criteria. This article will delve into the key aspects of patent claims, the recent USPTO guidance on AI-related inventions, and the broader patent landscape in the US.

Patent-Eligible Subject Matter Under Section 101

Section 101 of the Patent Act defines what constitutes patent-eligible subject matter, including processes, machines, manufactures, and compositions of matter. However, judicial exceptions have narrowed the scope of patent eligibility, particularly since the Supreme Court's decisions in cases like Bilski v. Kappos, Mayo Collaborative Servs. v. Prometheus Labs., and Alice Corp. v. CLS Bank[2].

The Alice/Mayo Framework

The Alice/Mayo framework is a two-step test used to determine patent eligibility:

  1. Determine if the claim is directed to a judicial exception (e.g., abstract ideas, natural phenomena, or laws of nature).
  2. Assess whether the claim elements, both individually and as an ordered combination, transform the nature of the claim into a patent-eligible application[2].

2024 USPTO Guidance Update on AI Patents

The 2024 USPTO guidance update, prompted by Executive Order 14110, aims to clarify the patent eligibility of AI-related inventions. Here are some key takeaways:

Evaluating Practical Applications

The guidance emphasizes the importance of evaluating whether a claim integrates a judicial exception into a practical application. This involves assessing additional elements in the claim to determine if they impose meaningful limits on the exception, thereby transforming the claim into patent-eligible subject matter[1].

AI-Assisted Inventions

The update clarifies that the method of invention development, including the use of AI, does not impact subject matter eligibility. Instead, the focus remains on the claimed invention itself, ensuring that AI-assisted inventions are evaluated on equal footing with other technologies, provided there is significant human contribution[1].

Incorporation of Recent Case Law

The guidance includes examples that illustrate how claims can be crafted to meet patent eligibility criteria. For instance, a claim that specifies the use of separated audio components in a real-time speech recognition system to enhance voice command accuracy is considered patent-eligible because it provides a practical application and tangible benefits[1].

The Importance of Claim Scope

Getting the claim scope right is critical in a US patent application. Here are some key points:

Avoiding Overly Broad Claims

While broader claims may offer broader protection, they are more difficult to get granted and easier to invalidate. Claims must be anchored to the embodiments in the disclosure and should avoid the abstract idea exception and failure to meet the written description requirement[3].

Balancing Breadth and Specificity

The claim scope should be balanced between being broad enough to cover the invention and specific enough to avoid invalidation. Overly broad claims can fall into the abstract idea exception, as seen in cases like Yu v. Apple Inc. and Alice v. CLS Bank[3].

Determining Inventorship

Inventorship is a critical aspect of patent law, and correctly determining who should be listed as an inventor is essential. In the US, an inventor is someone who conceives the subject matter of at least one claim of the patent and reduces the idea to practice[4].

Metrics for Measuring Patent Scope

Patent scope can be measured using metrics such as independent claim length and independent claim count. These metrics have explanatory power for several correlates of patent scope, including patent maintenance payments, forward citations, and novelty. Narrower claims at publication are associated with a higher probability of grant and a shorter examination process[5].

Practical Applications and Technological Improvements

To ensure patent eligibility, claims must demonstrate practical applications and technological improvements. For example, a claim that specifies the use of separated audio components in a speech recognition system to improve accuracy in hands-free environments is patent-eligible because it provides a tangible outcome that benefits the technology[1].

Legislative and Judicial Developments

There have been ongoing legislative and judicial developments aimed at clarifying and potentially reforming the standards for patent-eligible subject matter. Bills such as the Patent Eligibility Restoration Act of 2022 and 2023 have been introduced to replace the Alice/Mayo framework with narrower ineligible categories. However, the Supreme Court has been reluctant to revisit Section 101 issues, leaving the landscape in a state of flux[2].

Real-World Examples and Case Studies

Real-world examples, such as the comparison between Claim 1 and Claim 2 in the 2024 USPTO guidance, illustrate the importance of specifying practical applications. Claim 1, which merely uses a mathematical model without a specific application, is not patent-eligible, whereas Claim 2, which specifies the use in a real-time speech recognition system, is patent-eligible due to its practical application and tangible benefits[1].

Key Takeaways

  • Focus on Practical Applications: Claims must integrate judicial exceptions into practical applications to be patent-eligible.
  • AI-Assisted Inventions: The use of AI in invention development does not impact subject matter eligibility if there is significant human contribution.
  • Balanced Claim Scope: Claims should be balanced between breadth and specificity to avoid invalidation.
  • Inventorship: Correctly determining inventorship is crucial for patent validity.
  • Legislative and Judicial Developments: Ongoing efforts aim to clarify and reform patent-eligible subject matter standards.

FAQs

  1. What is the significance of the 2024 USPTO guidance update on AI patents? The update clarifies the process for determining the patent eligibility of AI-related inventions, emphasizing the integration of judicial exceptions into practical applications and ensuring AI-assisted inventions are evaluated on equal footing with other technologies.

  2. How does the Alice/Mayo framework impact patent eligibility? The Alice/Mayo framework is a two-step test that determines if a claim is directed to a judicial exception and whether the claim elements transform the nature of the claim into a patent-eligible application.

  3. Why is claim scope important in a US patent application? Claim scope is crucial because overly broad claims are more difficult to get granted and easier to invalidate, while narrower claims are more likely to be granted and less likely to be invalidated.

  4. What metrics can be used to measure patent scope? Metrics such as independent claim length and independent claim count can be used to measure patent scope, providing insights into the likelihood of grant and the examination process.

  5. How does inventorship impact patent validity? Correctly determining who should be listed as an inventor is essential for patent validity, as it involves conceiving the subject matter of at least one claim and reducing the idea to practice.

Sources

  1. Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz
  2. Patent-Eligible Subject Matter Reform: An Overview - CRS Reports
  3. The Importance of Getting the Claim Scope Right in a US Patent Application - Rimon Law
  4. Determining Inventorship for US Patent Applications - Oregon State University
  5. Patent Claims and Patent Scope - SSRN

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 11,311,541

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Kadmon Pharms Llc REZUROCK belumosudil mesylate TABLET;ORAL 214783-001 Jul 16, 2021 RX Yes Yes 11,311,541 ⤷  Subscribe TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 AND OLDER WITH SCLERODERMATOUS FORM OF CHRONIC GRAFT-VERSUS-HOST DISEASE ( CGVHD) AFTER FAILURE OF AT LEAST TWO PRIOR LINES OF SYSTEMIC THERAPY ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 11,311,541

PCT Information
PCT FiledApril 09, 2015PCT Application Number:PCT/US2015/025176
PCT Publication Date:October 15, 2015PCT Publication Number: WO2015/157556

International Family Members for US Patent 11,311,541

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO) 2015157556 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.